Fresenius Kabi Introduces New Presentation of Otulfi® (ustekinumab-aauz), a Biosimilar to Stelara® [Yahoo! Finance]
FRESENIUS SE S/ADR (FSNUY)
NASDAQ:AMEX Investor Relations:
fresenius.com/index
Company Research
Source: Yahoo! Finance
LAKE ZURICH, Ill., January 06, 2026 BUSINESS WIRE )--Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has introduced a new presentation of Otulfi ® (ustekinumab-aauz) in a 45 mg/0.5 mL single-dose vial for subcutaneous injection. Otulfi ® is a prescription medicine and the brand name for Fresenius Kabi's FDA-approved biosimilar of the reference product, Stelara ® (ustekinumab). With this addition, Fresenius Kabi now offers all dosage forms and strengths of the reference product, giving physicians flexibility and supporting patient treatment continuity. Fresenius Kabi's Otulfi ® has also received interchangeability designation from the FDA. Otulfi ® was approved by the U.S. Food and Drug Administration in September 2024 for the treatment of adults with moderately to severely active Crohn's disease and ulcerative colitis, and adults and pediatric patents ages 6 and older with moderate to se
Show less
Read more
Impact Snapshot
Event Time:
FSNUY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FSNUY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FSNUY alerts
High impacting FRESENIUS SE S/ADR news events
Weekly update
A roundup of the hottest topics
FSNUY
News
- Aspen Surgical Appoints Jørgen B. Hansen as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Opportunities and Competition in the $1.19 Billion U.S. IV Bags Market, 2025-2033, Featuring Baxter International, Kraton, Technoflex, B. Braun Medical, Sippex IV Bags and More [Yahoo! Finance]Yahoo! Finance
- AT&S Appoints Gerrit Steen as New CFO and Streamlines Its Executive Board [Yahoo! Finance]Yahoo! Finance
- Hercules Pharmaceuticals Appoints Ali Ahmed as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
- Fresenius SE & Co. (OTCMKTS:FSNUY) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat